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Colon cancer—4 (2.0 %) patients in acromegaly group and 
0 in control group (p = 0.14).
Conclusions Malignant neoplasms are significantly more 
common in patients with acromegaly. Particularly, risk 
of thyroid cancer was increased over fivefold. Systematic 
screening for neoplastic diseases should be important part 
of follow-up in these patients. Further case–control stud-
ies are strongly indicated to evaluate which neoplasms are 
more common in acromegalic patients and what is the exact 
risk of malignancy.
Keywords Acromegaly · Thyroid cancer · Colon cancer · 
Breast cancer · Pituitary
Introduction
Acromegaly is a chronic disease resulting from pathologi-
cal oversecretion of growth hormone (GH) and—in con-
sequence—insulin growth factor-1 (IGF-1) [1–4]. Several 
complications of the disease have been reported, including 
cardiovascular diseases, such as hypertrophic cardiomyopa-
thy, heart failure, hypertension, diabetes mellitus or respira-
tory disorders, obstructive sleep apnea but also increased 
risk of benign and malignant neoplasms [5–13].
The issue of the risk of benign and malignant neoplasms 
in acromegalic patients remains a topic of debate. Rokkas 
et al. [14] published a meta-analysis of colonoscopic stud-
ies, indicating significantly increased prevalence of colon 
adenomas, hyperplastic polyps and colon cancers. Wolin-
ski et al. [15] performed another meta-analysis showing 
an increased prevalence of nodular goiter and thyroid can-
cer (TC). Authors described a significantly increased risk 
of both disorders, and pooled OR for TCs was near eight. 
Published data considering the presence of other neoplasms 
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Purpose Acromegaly is a chronic disease resulting from 
pathological oversecretion of growth hormone and subse-
quently insulin growth factor-1. Several complications of 
the disease have been reported, including cardiovascular 
diseases, respiratory disorders but also increased risk of 
benign and malignant neoplasms. The aim of the study was 
to evaluate the risk of malignant neoplasms in the patients 
with acromegaly in comparison with the control group.
Patients and methods Medical documentation of acromeg-
alic patients treated in one medical center between 2005 
and 2016 has been analyzed. Results were compared with 
sex- and age-matched group of subjects with prolactinomas 
and hormonally inactive pituitary lesions hospitalized in 
the same department.
Results Two hundred patients with acromegaly were 
included. Control group was composed of 145 patients. 
Any malignant neoplasm in anamnesis was present in 27 
(13.5 %) patients with acromegaly and six (4.1 %) sub-
jects from control group (p = 0.003). Thyroid cancer was 
present in 14 (7.0 %) patients with acromegaly and two 
(1.4 %) in control group (p = 0.02). Breast cancer was 
present in seven women (5.4 % of women) in acromegaly 
group but none of subjects in control group (p = 0.02). 
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among the population of acromegalic individuals still 
remain very limited [9].
The aim of the study was to evaluate retrospectively 
the risk of malignant neoplasms in the patients with acro-
megaly, basing upon medical documentation from a single 




Medical documentation of acromegalic patients treated in 
one medical center (Department of Endocrinology, Metab-
olism and Internal Diseases in Poznan) between 2005 and 
June 2016 has been analyzed in order to find the informa-
tion about the presence of any neoplastic diseases. Results 
were compared with control group, comprising sex- and 
age-matched group of subjects with pituitary microadeno-
mas—hormonally inactive or prolactinomas—hospitalized 
in our department between 2010 and 2015.
The study was approved by The Poznan University of 
Medical Sciences Ethical Committee. Written informed 
consent was given by all participants.
Statistical analysis
All calculations were performed using Statistica v.12 soft-
ware with medical package (from StatSoft). Fisher’s exact 
test was used to compare the groups; p value under 0.05 
was considered significant.
Screening protocol
All patients hospitalized in our department undergo thyroid 
ultrasonography. In the case of patients with acromegaly, 
abdomen ultrasonography, chest X-ray and three times 
fecal occult blood test are performed during every hospital-
ization. All patients after diagnosis are also referred to the 
gastroenterological outpatient clinic for the further follow-
up. There is no routine screening for other malignancies—
in concordance with the guidelines [16]—as increased risk 
of malignancy was evidenced only for these two malignan-
cies. Data on other neoplasms come from anamnesis.
Results
Two hundred patients with acromegaly, encompassing 129 
women (64.5 %) and 71 men (35.5 %), were included. 
Mean age was 53.3, and standard deviation (SD) 12.2 years. 
Control group was composed of 145 patients with pituitary 
microadenomas, including 99 women (68.3 %) and 46 
men, mean age was 51.9, and SD 14.8 years. Differences 
referring to percentage of woman and mean age were not 
significant (p > 0.05).
Mean age at the time of diagnosis of acromegaly was 
47.6 years, SD 13.0, and range 17–79 years. Mean duration 
of acromegaly at the end of follow-up was 5.6 years, SD 
7.1, and range 0–38 years.
Any malignant neoplasm in anamnesis was present in 27 
(13.5 %) patients with acromegaly and six (4.1 %) subjects 
from control group (p = 0.003). OR was 3.6 with 95 % con-
fidence interval (CI) 1.5–9.0, and risk ratio (RR) was 3.3 with 
95 % CI 1.4–7.7. TC was present in 14 (7.0 %) patients with 
acromegaly and two (1.4 %) in control group (p = 0.02). 
Among acromegalic patients, thirteen had papillary TC 
(PTC) and one had follicular thyroid cancer (FTC). In control 
group, both patients had PTC. OR for TCs was 5.4 with 95 % 
CI 1.2–24.1, and RR was 5.1 with 95 % CI 1.7–22.0.
Breast cancer (BC) was present in seven women (5.4 % 
of women) in acromegaly group but none of subjects in 
control group (p = 0.02). OR and RR are incalculable due 
to lack of affected subjects in the control group; OR and 
RR achieved by adding a constant (0.5) to all cells in the 
contingency table would be 12.2 and 11.5, respectively. 
Colon cancer was present in four (2.0 %) patients in acro-
megaly group and 0 in control group (p = 0.14). Other 
malignancies in the studied group included one neuroendo-
crine tumor of pancreas, one squamous cell cancer of the 
skin, one ovarian cancer and one leiomyosarcoma of the 
uterine. One patient had three malignancies—breast cancer, 
thyroid cancer and leiomyosarcoma of the uterine. In the 
control group, there were one neuroendocrine tumor of the 
duodenum, one lung cancer and one prostate cancer.
In patients with TC, mean age at the time of diagnosis was 
52.6 years, SD 10.2, median 49.5, and range 39–67 years. In 
two patients, TC was diagnosed before acromegaly (4 years 
in both subjects), in three patients both diseases were diag-
nosed in the same year, and in nine cases TC was diagnosed 
posteriorly (4, 5, 8, 10, 12, 15, 16, 19 and 20 years).
In patients with BC, mean age at the time of diagnosis 
was 48.7 years, SD 9.2, median 51, range 36–62 years. In 
four patients, BC was diagnosed before acromegaly (4, 7, 7 
and 16 years), in one patient both diseases were diagnosed 
in the same year, and in two cases BC was diagnosed poste-
riorly (4 and 11 years).
Taking all 29 malignant neoplasms into account, nine 
of them were diagnosed before acromegaly (two TCs, four 
BCs, two colon cancers and one leiomyosarcoma of the 
uterine): In one case, surgeon performing the hemicolec-
tomy due to the colon cancer raised the suspicion of acro-
megaly and referred the patient to the endocrine depart-
ment, and in remaining seven cases, the malignancy was 
diagnosed at least four years before acromegaly. In five 
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cases (three TCs, one BC and one ovarian cancer in the 
metastatic phase), malignant neoplasm was diagnosed dur-
ing the comprehensive examinations just after the diagno-
sis of acromegaly (diagnosis or suspicion made during the 
hospitalization in the endocrine department). Fifteen fur-
ther malignancies (nine TCs, two BCs, two colon cancers, 
one squamous cell cancer of the skin, one neuroendocrine 
tumor) were diagnosed after acromegaly.
Discussion
According to our results, patients with acromegaly pre-
sented increased risk of neoplastic disease; the risk of 
development of any kind of malignant tumor was over three 
times higher than in the control group. It is worth noticing 
that in group with mean age slightly over 50 years over one 
in eight patients was diagnosed with malignant neoplasm. 
It also calls attention that in majority of patients malignant 
neoplasms were diagnosed in parallel or subsequently to 
the diagnosis of acromegaly; this result indicates the great 
importance of systematic and comprehensive screening for 
neoplastic diseases in these patients.
Among malignancies, the risk of thyroid cancer was sig-
nificantly and most strongly elevated with RR exceeding 
five. This result is quite similar to the pooled prevalence of 
the neoplastic transformations in this subpopulation reported 
in meta-analysis concerning the issue [15]. Also the increase 
in prevalence of breast cancer was significant, and the differ-
ence in prevalence of colon cancer was of borderline signifi-
cance. Other neoplasms occurred in single patients.
Such a high number of subjects with diagnosed thyroid 
malignancies can be partially explained by the fact that 
every patient in our department—irrespective of the initial 
diagnosis—undergoes thyroid ultrasonography as a rou-
tine procedure. As a consequence probably all TCs were 
detected and described in medical documentation, includ-
ing early-stage cancers which would probably remain non-
symptomatic for years. In the case of other malignancies 
data comes mainly from anamnesis, so the real prevalence 
of identifiable disorders can be underestimated. On the other 
hand, according to the meta-analysis published by Wolin´ski 
et al. [15] the pooled prevalence of thyroid cancer in acro-
megalic patients calculated on the basis of studies published 
between 2008 and 2013 was surprisingly high—almost 6 %. 
The current result is in compliance with this outcome.
There was a plenty of literature concerning the issue 
of malignant neoplasms in patients with acromegaly [5, 
8, 14, 15]. However, most studies described subjects with 
acromegaly without comparison to control group (e.g., [3, 
17, 18]) or the results were compared with the data from 
local cancer registries (e.g., [19–22]). Amount of case–con-
trol studies, especially describing large groups of patients, 
is very limited. Wolinski et al. [15] meta-analyzed the 
risk of TC in patients with acromegaly indicating strongly 
increased prevalence of the disease. However, only five 
case–control studies on the topic were identified. Rokkas 
et al. [14] combined results of studies assessing the risk of 
colon cancer—only three studies meeting inclusion criteria 
were enrolled in the final analysis. In consequence, despite 
the fact that results of both meta-analyses were statistically 
significant, confidence intervals were very broad and the 
precise estimation of effect size and subsequently clinical 
significance of findings is not possible. To give an exam-
ple, Wolinski et al. [15] reported pooled OR for TC to be 
slightly under eight with 95 % CI 2.8–22.0. The study evi-
denced an increased prevalence of TC, but in fact whether 
we are dealing with slight increase or vast elevation of the 
risk remains unclear.
In the case of other neoplasms, the amount of data is 
very limited. Nabarro et al. [3] described high prevalence of 
breast cancer, about four times higher than expected, basing 
upon the epidemiological data. Eleven of 123 women were 
affected. Barris et al. [20] found only an insignificantly 
increased risk in comparison with the amount expected 
on the basis of cancer registry, and similar results were 
presented by Petroff et al. [23]. In the study published by 
Popovic et al. [24]—the only previously published case–
control study assessing the prevalence of breast cancer—
the risk was insignificantly higher in acromegalic patients. 
Four of 133 women in the study group and one of 153 
women in control group presented such malignancy. Our 
study discloses significantly higher prevalence of breast 
cancer. The issue is vital as guidelines concerning man-
agement of patients with acromegaly do not include any 
screening for mammary tumors [16, 25]. Secondly, as some 
authors question the clinical significance of the increased 
prevalence of thyroid cancer in patients with acromegaly 
and consequently of active screening for that malignancy 
due to relatively slow development of the disease and good 
prognosis [26], clinical significance of breast cancer and its 
early diagnosis is undoubted. Further studies on the topic 
are strongly desirable. There are also a few reports about 
the increased prevalence of renal cancer and tumors of the 
central nervous system [8, 20] which were not supported by 
our results.
In conclusion, malignant neoplasms are significantly 
more common in patients with acromegaly. Particu-
larly, risk of thyroid cancer was increased over fivefold; 
increased risk of breast cancer remains questionable but 
clinically important issue. Systematic screening for neo-
plastic diseases should be important part of the follow-up 
in these patients. Further case–control studies are strongly 
indicated to evaluate which neoplasms are more common 
in acromegalic patients and to assess more precisely the 
exact risk of malignancy.
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